Tìm theo
Quinidine barbiturate
Thuốc Gốc
Small Molecule
CTHH: C32H36N4O5
PTK: 556.652
The administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C32H36N4O5
Phân tử khối
556.652
Monoisotopic mass
556.268570282
InChI
InChI=1S/C20H24N2O2.C12H12N2O3/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;3-7H,2H2,1H3,(H2,13,14,15,16,17)
InChI Key
InChIKey=YHRUERMOPBDCFD-UHFFFAOYSA-N
IUPAC Name
5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(6-methoxyquinolin-4-yl)methanol
Traditional IUPAC Name
phenobarbital; quinine
SMILES
CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
logP
2.51
pKa (strongest acidic)
13.89
pKa (Strongest Basic)
9.05
PSA
45.59 Å2
Refractivity
94.69 m3·mol-1
Polarizability
35.97 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
4
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
6
Bioavailability
1
MDDR-Like Rule
true
Cơ Chế Tác Dụng : The administration of quinidine derivatives helps to observe various skin and mucosal reactions. A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909) Barbiturates work by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS.
Tương Tác Thuốc :
  • Amiloride Decreases the antiarrhythmic effect of quinidine
  • Aminophylline The barbiturate, quinidine barbiturate, decreases the effect of aminophylline.
  • Amiodarone Increases the effect of qiunidine
  • Amitriptyline Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline.
  • Aripiprazole Quinidine increases the effect and toxicity of aripiprazole
  • Atazanavir Increased risk of cardiotoxicity and arrhythmias
  • Atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
  • Betamethasone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone.
  • Cimetidine Increases the effect of quinidine
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Clarithromycin Increased risk of cardiotoxicity and arrhythmias
  • Clomipramine Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine.
  • Codeine Quinidine decreases the analgesic effect of codeine
  • Cyclosporine The barbiturate, quinidine barbiturate, increases the effect of cyclosporine.
  • Desipramine Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine.
  • Dexamethasone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone.
  • Dextromethorphan Quinidine increases the toxicity of dextromethorphan
  • Digoxin Quinine/quinidine increases the effect of digoxin
  • Diltiazem Increases the effect and toxicity of quinidine
  • Donepezil Possible antagonism of action
  • Doxepin Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin.
  • Doxycycline The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline.
  • Erythromycin Increased risk of cardiotoxicity and arrhythmias
  • Felodipine The barbiturate, quinidine barbiturate, decreases the effect of felodipine.
  • Fludrocortisone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone.
  • Folic Acid Folic acid decreases the effect of anticonvulsant, quinidine barbiturate.
  • Galantamine Possible antagonism of action
  • Gatifloxacin Increased risk of cardiotoxicity and arrhythmias
  • Gefitinib The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.
  • Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
  • Griseofulvin The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin.
  • Hydrocortisone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
  • Imipramine Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine.
  • Itraconazole Itraconazole may increase the effect and toxicity of quinidine barbiturate.
  • Ketoconazole Ketoconazole may increase the effect and toxicity of quinidine barbiturate.
  • Levofloxacin Increased risk of cardiotoxicity and arrhythmias
  • Levonorgestrel Phenobarbital decreases the effect of levonorgestrel
  • Magnesium The antiacid decreases the absorption of quinidine
  • Mesoridazine Increased risk of cardiotoxicity and arrhythmias
  • Methadone The barbiturate, quinidine barbiturate, decreases the effect of methadone.
  • Metronidazole The barbiturate, quinidine barbiturate, decreases the effect of metronidazole.
  • Moxifloxacin Increased risk of cardiotoxicity and arrhythmias
  • Nelfinavir Nelfinavir increases the effect and toxicity of quinidine
  • Nifedipine Decreased quinidine effect, increased nifedipine effect
  • Nortriptyline Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline.
  • Ofloxacin Increased risk of cardiotoxicity and arrhythmias
  • Oxtriphylline The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline.
  • Prednisolone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone.
  • Prednisone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
  • Procainamide Quinidine increases the effect of procainamide
  • Propafenone Quinidine increases the effect of propafenone
  • Quinidine The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine.
  • Quinupristin This combination presents an increased risk of toxicity
  • Rifampicin Rifampin decreases the effect of quinidine
  • Telithromycin Increased risk of cardiotoxicity and arrhythmias
  • Theophylline The barbiturate, quinidine barbiturate, decreases the effect of theophylline.
  • Thioridazine Increased risk of cardiotoxicity and arrhythmias
  • Triamcinolone The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01346
PharmGKB
http://www.pharmgkb.org/drug/PA164783957
... loading
... loading